FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
Executive Summary
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
You may also be interested in...
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting
Vaccines And Advair Keep GSK’s Earnings Steady Despite Avandia Losses
Despite losses from generic competition and falling Avandia sales, strong performances from GlaxoSmithKline's vaccines business and asthma therapy Advair kept its third quarter earnings fairly consistent with the year-ago period